New drug combo aims to shrink Hard-to-Treat pancreatic and ovarian tumors
NCT ID NCT04616534
First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time
Summary
This phase 1 trial tests a combination of the chemotherapy drug gemcitabine and the targeted drug elimusertib in people with advanced pancreatic, ovarian, or other solid tumors that have spread. The goal is to find the safest dose and see whether the combination can shrink or stabilize tumors. Participants receive both drugs by mouth or IV, and the study monitors side effects and tumor response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- gemcitabine and elimusertib
- What this could lead to
- If it works, this combination could shrink or stabilize advanced pancreatic, ovarian, and other solid tumors, offering a new treatment option for patients who have run out of standard therapies.
- What could go wrong
- This is an early phase 1 trial with only 14 participants, so the results are preliminary. The combination may cause significant side effects, and the maximum tolerated dose was not reached due to toxicity, meaning the risks may outweigh benefits for some patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED FALLOPIAN TUBE CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
National Cancer Institute Developmental Therapeutics Clinic
Bethesda, Maryland, 20892, United States
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can High-Dose vitamin c boost chemo against pancreatic cancer?
- Could a Decades-Old parasite drug help fight pancreatic cancer?
- Could a nerve zap stop cancer wasting? early trial tests device for cachexia
- New Antibody-Drug combo takes on Hard-to-Treat pancreatic cancer
- Engineered immune cells take aim at Hard-to-Treat cancers
- Drug cocktail aims to stall pancreatic cancer in patients who have run out of options